Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis

Vasopressin for refractory hypotension during cardiopulmonary bypass.

Dermal tattooing following intravenous methylene blue for refractory hypotension after coronary artery bypass grafting

The authors present an image of a middle-aged male after coronary artery bypass grafting who received intravenous methylene blue for refractory hypotension that resulted in dermal tattooing/staining of the venous vasculature of his left shoulder and left upper chest. Republished with permission from: Bhatt AM, Tripathi RS, Moran KR, Papadimos TJ. Dermal tattooing following intravenous methylene...

Methylene blue for refractory hypotension: a case report.

Methylene blue has multiple indications for use, but recently it has been shown to be useful in treating refractory hypotension. Anaphylaxis results in widespread vasodilation and hypotension. Epinephrine has been described as the drug of choice in the treatment of hypotension for anaphylaxis, but the increased heart rate may be poorly tolerated by some patients. This case report describes a 79...

Methylene blue as drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass.

OBJECTIVES Vasoplegia is a frequent complication after cardiopulmonary bypass that often requires the application of norepinephrine. In a number of cases, however, vasoplegia is refractory to norepinephrine. The guanylate cyclase inhibitor methylene blue could be an attractive treatment alternative in such cases. This study examines the results of methylene blue therapy for norepinephrine-refra...

[Methylene blue to treat anaphylaxis during anesthesia: case report.].

BACKGROUND AND OBJECTIVES The risk of perioperative anaphylaxis should always be considered. The incidence of anesthetic allergic reactions is controversial, varying from 1/3,000 to 1/20,000, with mortality range between 3 and 9%. This report describes the use of methylene blue as coadjuvant drug to treat anaphylaxis refractory to conventional therapy. CASE REPORT A 53-year-old male patient w...